Molecular dynamics simulation of the crystallizable fragment of IgG1-Insights for the design of Fcabs

International Journal of Molecular Sciences

Volumn 15, Issue 1, 2014, Pages 438-455

  Lai, Balder ^a   Hasenhindl, Christoph ^a   Obinger, Christian ^a   Oostenbrink, Chris ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Crystallizable Fc fragment; Molecular dynamics simulations; Molecular modeling; Monoclonal antibody

Indexed keywords

IMMUNOGLOBULIN G1; MOLECULAR SCAFFOLD; MONOCLONAL ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ANTIBODY COMBINING SITE; ARTICLE; COMPUTER SIMULATION; CONFORMATIONAL TRANSITION; CRYSTALLIZATION; DATA ANALYSIS; HUMAN; INFORMATION PROCESSING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PH; POINT MUTATION; PROTEIN ANALYSIS; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; X RAY CRYSTALLOGRAPHY; CARBOHYDRATE ANALYSIS; CHEMISTRY; GENETICS; GLYCOSYLATION; HYDROGEN BOND; METABOLISM; MOLECULAR GENETICS; MUTATION; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE;

CARBOHYDRATE SEQUENCE; CRYSTALLOGRAPHY, X-RAY; GLYCOSYLATION; HUMANS; HYDROGEN BONDING; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY;

EID: 84891771146     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15010438     Document Type: Article

References (51)

1. Strebhardt, K.; Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 2008, 8, 473-480.
2. Ehrlich, P. Über Den Jetzigen Stand Der Karzinomforschung (in Germany). In Beiträge zur Experimentellen Pathologie und Chemotherapie; Akademische Verlagsgesellschaft: Leipzig, Germany, 1909; pp. 117-164.
3. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
4. Teillaud, J. From Whole Monoclonal Antibodies to Single Domain Antibodies: Think Small. In Single Domain Antibodies; Saerens, D., Muyldermans, S., Eds.; Humana Press: Totowa, NJ, USA, 2012; Volume 911, pp. 3-13.
5. Chames, P.; van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br. J. Pharmacol. 2009, 157, 220-233.
6. Ruuls, S.R.; Lammerts van Bueren, J.J.; van de Winkel, J.G.; Parren, P.W. Novel human antibody therapeutics: The age of the Umabs. Biotechnol. J. 2008, 3, 1157-1171.
7. Jakobovits, A.; Amado, R.G.; Yang, X.; Roskos, L.; Schwab, G. From XenoMouse technology to Panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 2007, 25, 1134-1143.
8. Feldhaus, M.J.; Siegel, R.W. Yeast display of antibody fragments: A discovery and characterization platform. J. Immunol. Methods 2004, 290, 69-80.
9. Carter, P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6, 343-357.
10. Arnold, J.N.; Wormald, M.R.; Sim, R.B.; Rudd, P.M.; Dwek, R.A. the impact of glycosylation on the biological function and structure of human immunoglobulins. Ann. Rev. Immunol. 2007, 25, 21-50.
11. Bradbury, A.R.; Sidhu, S.; Dubel, S.; McCafferty, J. Beyond natural antibodies: The power of in vitro display technologies. Nat. Biotechnol. 2011, 29, 245-254.
12. Nelson, A.L.; Dhimolea, E.; Reichert, J.M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010, 9, 767-774.
13. Moore, P.L.; Gray, E.S.; Wibmer, C.K.; Bhiman, J.N.; Nonyane, M.; Sheward, D.J.; Hermanus, T.; Bajimaya, S.; Tumba, N.L.; Abrahams, M.R.; et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 2012, 18, 1688-1692.
14. Garber, K. Genentech's alzheimer's antibody trial to study disease prevention. Nat. Biotechnol. 2012, 30, 731-732.
15. Hino, T.; Arakawa, T.; Iwanari, H.; Yurugi-Kobayashi, T.; Ikeda-Suno, C.; Nakada-Nakura, Y.; Kusano-Arai, O.; Weyand, S.; Shimamura, T.; Nomura, N.; et al. G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 2012, 482, 237-240.
16. Vincent, K.J.; Zurini, M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. Biotechnol. J. 2012, 7, 1444-1450.
17. Hudson, P.J. Recombinant antibody fragments. Curr. Opin. Biotechnol. 1998, 9, 395-402.
18. Holliger, P.; Hudson, P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23, 1126-1136.
19. De Marco, A. Biotechnological applications of recombinant single-domain antibody fragments. Microb. Cell Fact. 2011, doi:10.1186/1475-2859-10-44.
20. Zahnd, C.; Pecorari, F.; Straumann, N.; Wyler, E.; Pluckthun, A. Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J. Biol. Chem. 2006, 281, 35167-35175.
21. Orlova, A.; Magnusson, M.; Eriksson, T.L.; Nilsson, M.; Larsson, B.; Hoiden-Guthenberg, I.; Widstrom, C.; Carlsson, J.; Tolmachev, V.; Ståhl, S.; et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006, 66, 4339-4348.
22. Dimitrov, D.S. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010, 2, 347-356.
23. Boersma, Y.L.; Pluckthun, A. DARPins and other repeat protein scaffolds: Advances in engineering and applications. Curr. Opin. Biotechnol. 2011, 22, 849-857.
24. Wozniak-Knopp, G.; Bartl, S.; Bauer, A.; Mostageer, M.; Woisetschlager, M.; Antes, B.; Ettl, K.; Kainer, M.; Weberhofer, G.; Wiederkum, S.; et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng. Des. Sel. 2010, 23, 289-297.
25. Ying, T.; Chen, W.; Gong, R.; Feng, Y.; Dimitrov, D.S. Soluble monomeric IgG1 Fc. J. Biol. Chem. 2012, 287, 19399-19408.
26. Ying, T.; Chen, W.; Feng, Y.; Wang, Y.; Gong, R.; Dimitrov, D.S. Engineered soluble monomeric IgG1 CH3 domain: Generation, mechanism of function, and implications for design of biological therapeutics. J. Biol. Chem. 2013, 288, 25154-25164.
27. Kabat, E.A.; Wu, T.T.; Gottesman, K.S.; Foeller, C. Sequences of Proteins of Immunological Interest; Diane Publishing Company: Collingdale, PA, USA, 1992.
28. Kontermann, R. Dual targeting strategies with bispecific antibodies. MAbs 2012, 4, 182-197.
29. Traxlmayr, M.W.; Wozniak-Knopp, G.; Antes, B.; Stadlmayr, G.; Ruker, F.; Obinger, C.Integrin binding human antibody constant domains-Probing the C-terminal structural loops for grafting the RGD motif. J. Biotechnol. 2011, 155, 193-202.
30. Traxlmayr, M.W.; Faissner, M.; Stadlmayr, G.; Hasenhindl, C.; Antes, B.; Ruker, F.; Obinger, C. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim. Biophys. Acta 2012, 1824, 542-549.
31. Hu, G.; Zhang, Q.; Chen, L.Y. Insights into scFv: Drug binding using the molecular dynamics simulation and free energy calculation. J. Mol. Model. 2011, 17, 1919-1926.
32. De Ruiter, A.; Mader, A.; Kunert, R.; Oostenbrink, C. Molecular simulations to rationalize humanized Ab2/3H6 activity. Aust. J. Chem. 2011, 64, 900-909.
33. Wang, X.; Kumar, S.; Buck, P.M.; Singh, S.K. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: Observations from molecular dynamics simulations. Proteins 2013, 81, 443-460.
34. Kortkhonjia, E.; Brandman, R.; Zhou, J.Z.; Voelz, V.A.; Chorny, I.; Kabakoff, B.; Patapoff, T.W.; Dill, K.A.; Swartz, T.E. Probing antibody internal dynamics with fluorescence anisotropy and molecular dynamics simulations. MAbs 2013, 5, 306-322.
35. Traxlmayr, M.W.; Hasenhindl, C.; Hackl, M.; Stadlmayr, G.; Rybka, J.D.; Borth, N.; Grillari, J.; Rüker, F.; Obinger, C. Construction of a stability landscape of the CH3 domain of human IgG1 by combining directed evolution with high throughput sequencing. J. Mol. Biol. 2012, 423, 397-412.
36. Hasenhindl, C.; Traxlmayr, M.W.; Wozniak-Knopp, G.; Jones, P.C.; Stadlmayr, G.; Rüker, F.; Obinger, C. Stability assessment on a library scale: A rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc. Protein Eng. Des. Sel. 2013, 26, 675-682.
37. Meier, S.; Duus, J. Carbohydrate dynamics: Antibody glycans wiggle and jiggle. Nat. Chem. Biol.2011, 7, 131-132.
38. Schmid, N.; Christ, C.D.; Christen, M.; Eichenberger, A.P.; van Gunsteren, W.F. Architecture, implementation and parallelisation of the GROMOS software for biomolecular simulation. Comput. Phys. Commun. 2012, 183, 890-903.
39. Eichenberger, A.P.; Allison, J.R.; Dolenc, J.; Geerke, D.P.; Horta, B.A.C.; Meier, K.; Oostenbrink, C.; Schmid, N.; Steiner, D.; Wang, D.; et al. GROMOS++ Software for the analysis of biomolecular simulation trajectories. J. Chem. Theory Comput. 2011, 7, 3379-3390.
40. Saphire, E.O.; Parren, P.W.; Pantophlet, R.; Zwick, M.B.; Morris, G.M.; Rudd, P.M.; Dwek, R.A.; Stanfield, R.L.; Burton, D.R.; Wilson, I.A. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design. Science 2001, 293, 1155-1159.
41. Schmid, N.; Eichenberger, A.; Choutko, A.; Riniker, S.; Winger, M.; Mark, A.; van Gunsteren, W. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur. Biophys. J. 2011, 40, 843-856.
42. Hansen, H.S.; Hunenberger, P.H. A reoptimized GROMOS force field for hexopyranose-based carbohydrates accounting for the relative free energies of ring conformers, anomers, epimers, hydroxymethyl rotamers, and glycosidic linkage conformers. J. Comput. Chem. 2011, 32, 998-1032.
43. Berendsen, H.; Postma, J.; van Gunsteren, W.; Hermans, J. Interaction Models for Water in Relation to Protein Hydration. In Intermolecular Forces; Pullman, B., Ed.; D. Reidel Publishing Company: Boston, MA, USA, 1981; pp. 331-342.
44. Berendsen, H.J.C.; Postma, J.P.M.; van Gunsteren, W.F.; DiNola, A.; Haak, J.R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, 3684-3690.
45. Hockney, R.W. The potential calculation and some applications. Methods Comput. Phys. 1970, 9, 136-211.
46. Ryckaert, J.; Ciccotti, G.; Berendsen, H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of N-alkanes. J. Comput. Phys. 1977, 23, 327-341.
47. Heinz, T.N.; Hünenberger, P.H. A fast pairlist-construction algorithm for molecular simulations under periodic boundary conditions. J. Comput. Chem. 2004, 25, 1474-1486.
48. Tironi, I.G.; Sperb, R.; Smith, P.E.; van Gunsteren, W.F. A generalized reaction field method for molecular dynamics simulations. J. Chem. Phys. 1995, 102, 5451-5459.
49. Heinz, T.N.; van Gunsteren, W.F.; Hünenberger, P.H. Comparison of four methods to compute the dielectric permittivity of liquids from molecular dynamics simulations. J. Chem. Phys. 2001, 115, 1125-1136.
50. Schmid, N.; Botschi, M.; van Gunsteren, W.F. A GPU solvent-solvent interaction calculation accelerator for biomolecular simulations using the GROMOS software. J. Comput. Chem. 2010, 31, 1636-1643.
51. Vetterling, W.; Flannery, B. Numerical Recipes in C++: The Art of Scientific Computing; Cambridge University Press: Cambridge, UK, 2002.